CINRYZE®▼
C1 inhibitor (human)

Patient Diary

This document has been reviewed and approved by The Saudi Food and Drug Authority (SFDA).

Please use this diary to record the date, lot numbers, and reason for injection each time you inject CINRYZE (C1 esterase inhibitor [human]) and share this information with your treating physician at your next visit.

Reporting of side effects

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly to Takeda: ae.saudiarabia@takeda.com. By reporting side effects you can help provide more information on the safety of this medicine.

To report any side effects in Saudi Arabia:
The National Pharmacovigilance and Drug Safety Centre (NPC)
Website: https://ade.sfda.gov.sa/
Toll free phone: 19999
E-mail: npc.drug@sfda.gov.sa

Date of injection	Time of injection	Vial lot numbers	Expiry date(s)	Reason for injection	Dose Received	Response to Treatment	Adverse Reactions
				☐ Treatment of attack ☐ Routine prevention ☐ Pre-procedure			
				☐ Treatment of attack ☐ Routine prevention ☐ Pre-procedure			
				☐ Treatment of attack ☐ Routine prevention ☐ Pre-procedure			
				☐ Treatment of attack ☐ Routine prevention ☐ Pre-procedure			
				☐ Treatment of attack ☐ Routine prevention ☐ Pre-procedure			
				☐ Treatment of attack ☐ Routine prevention ☐ Pre-procedure			
				☐ Treatment of attack ☐ Routine prevention ☐ Pre-procedure			
				☐ Treatment of attack ☐ Routine prevention ☐ Pre-procedure			
				☐ Treatment of attack ☐ Routine prevention ☐ Pre-procedure			
				☐ Treatment of attack ☐ Routine prevention ☐ Pre-procedure			
				☐ Treatment of attack ☐ Routine prevention ☐ Pre-procedure			
				☐ Treatment of attack ☐ Routine prevention ☐ Pre-procedure			

VV-MEDMAT-59572